Celltrion Presents Real-World Data of Truxima (biosimilar- rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021
Shots:
- The new data from the post-approval study evaluates the effectiveness & safety of Truxima (CT-P10) in patients with DLBCL in a real-world setting across Europe
- Results: @30mos. post-index- 67% had not experienced disease progression with OS (74%)- three-quarters patients achieved complete or partial response @30mos.- well tolerated with AEs while response rates- survival rates & overall safety profile showed consistency with reference product
- The company also presents real-world data of CT-P10 for NHL & CLL which showed 10% of patients experienced an IRR & were generally well-tolerated- patients achieved a complete response or partial response @6mos. observation period
| Ref: Business Wire | Image: Celltrion
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
